<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513355</url>
  </required_header>
  <id_info>
    <org_study_id>JS-ENDO-001</org_study_id>
    <nct_id>NCT02513355</nct_id>
  </id_info>
  <brief_title>Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing NingQi Medicine Science and Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing NingQi Medicine Science and Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research purpose:&#xD;
&#xD;
      Degree of continuous intravenous pumping Endostar (human recombinant endostatin) combination&#xD;
      chemotherapy regimens including cisplatin two medicine first-line treatment of advanced&#xD;
      non-small cell lung cancer (with the exception of EGFR/ALK mutations) efficacy and safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1.Research purpose: Degree of continuous intravenous pumping Endostar (human recombinant&#xD;
      endostatin) combination chemotherapy regimens including cisplatin two medicine first-line&#xD;
      treatment of advanced non-small cell lung cancer (with the exception of EGFR/ALK mutations)&#xD;
      efficacy and safety.&#xD;
&#xD;
      2.1 main objectives: PFS 2.2 the secondary goal: 2.2. 1 ORR, DCR and OS 2.2. 2 the quality of&#xD;
      life 3. The study design 3.1 research nature This is a single arm, multicenter clinical&#xD;
      study, is expected to total 100 patients into the group.&#xD;
&#xD;
      Hierarchical factors include: the tumor staging (Ⅲ B vs Ⅳ), ECOG score (0 v 1), gender (male&#xD;
      vs female).&#xD;
&#xD;
      3.2 research center and research Proposed by taizhou people's hospital and medical&#xD;
      association of jiangsu province tumor chemotherapy and biological branch of the lung cancer&#xD;
      group led by several large and medium-sized hospitals in the province of the malignant tumor&#xD;
      treatment related department to participate, in accordance with the unified test plan of this&#xD;
      research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS（progression-free survival）</measure>
    <time_frame>Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase</time_frame>
    <description>PFS is refers to the patients randomly into group to the date of any objective records of patients with tumor progression or death time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR（Objective Response Rate）</measure>
    <time_frame>1 weeks before treatment, Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR(disease control rate)</measure>
    <time_frame>Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS（overall survival）</measure>
    <time_frame>Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NP(Changchun marina+cisplatin)+Endostar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will be given conventional chemotherapy medicine,NP plan (Changchun marina+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer. Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles;Changchun marina;25mg/m2,d1 and d8,cisplatin 80mg/m2,d1, q21d×4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TP(Taxol+cisplatin or parapl) +Endostar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will be given conventional chemotherapy medicine,TP(Taxol+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer.&#xD;
Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles; Taxol;135-175mg/m2,d1,cisplatin or parapl 75mg/m2,d1,q21d×4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles</description>
    <arm_group_label>NP(Changchun marina+cisplatin)+Endostar</arm_group_label>
    <arm_group_label>TP(Taxol+cisplatin or parapl) +Endostar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Changchun marina</intervention_name>
    <description>25mg/m2,d1 and d8,q21d×4</description>
    <arm_group_label>NP(Changchun marina+cisplatin)+Endostar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>80mg/m2,d1, q21d×4</description>
    <arm_group_label>NP(Changchun marina+cisplatin)+Endostar</arm_group_label>
    <arm_group_label>TP(Taxol+cisplatin or parapl) +Endostar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxol</intervention_name>
    <description>135-175mg/m2,d1,q21d×4</description>
    <arm_group_label>TP(Taxol+cisplatin or parapl) +Endostar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>parapl</intervention_name>
    <description>AUC=5-6,d1,q21d×4</description>
    <arm_group_label>TP(Taxol+cisplatin or parapl) +Endostar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic confirmation cytology or not in patients undergoing single sputum cytology&#xD;
             in the diagnosis of patients with non-small cell lung cancer;&#xD;
&#xD;
          -  according to a new IASLC2009 lung cancer TNM stages judged the preious untreated stage&#xD;
             IIIB or IV non-small cell lung cancer (with the exception of EGFR/ALK mutations type);&#xD;
&#xD;
          -  must have at least one according to the RRECIST version 1.1 standard judgment to&#xD;
             evaluate lesions (at least 10 mm, maximum diameter on spiral CT plain CT longest&#xD;
             diameter at least 20 mm);&#xD;
&#xD;
          -  male or female, age 18 and 75 years old or less or more;&#xD;
&#xD;
          -  ECOG PS 0 ~ 1 minute;&#xD;
&#xD;
          -  is expected to survive period for 3 months or more,&#xD;
&#xD;
          -  enough blood function: absolute neutrophil count (ANC) or 2 x 109 / L and the platelet&#xD;
             count 100 x 109 / L or higher acuity 9 g/dL and hemoglobin;&#xD;
&#xD;
          -  Liver function enough: upper limit of total bilirubin acuities were normal (ULN); AST&#xD;
             and ALT acuities were 2.5 times the upper limit of normal (ULN); Alkaline phosphatase&#xD;
             5 times the upper limit of normal or less (ULN);&#xD;
&#xD;
          -  enough renal function, serum creatinine or less normal limit (ULN) or calculated&#xD;
             creatinine clearance or 60 mL/min.&#xD;
&#xD;
          -  basic normal ecg, had on the body to heal wounds;&#xD;
&#xD;
          -  always not received anti-tumor drug therapy, or always only for non metastatic tumor&#xD;
             of adjuvant or neoadjuvant chemotherapy, but to study treatment has ended more than&#xD;
             six months at the beginning;&#xD;
&#xD;
          -  ever had had surgery patients, request to study treatment began to have more than 4&#xD;
             weeks, and the patient has recovered;&#xD;
&#xD;
          -  a complete uterus of female in the group within 28 days before the study must have a&#xD;
             negative pregnancy test results (except amenorrhea has 24 months). If the pregnancy&#xD;
             test from the first time for more than 7 days, is the need for urine pregnancy test&#xD;
             validation (within 7 days before the first delivery).&#xD;
&#xD;
          -  prior to biological agents, especially e. coli genetically engineered products without&#xD;
             severe allergic reactions;&#xD;
&#xD;
          -  signed informed consent.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  pregnancy, nursing mothers, or fertility but not women using contraception;&#xD;
&#xD;
          -  the existing serious acute infection, and not be controlled; Or fester sex and chronic&#xD;
             infection, wound in delay no more;&#xD;
&#xD;
          -  the original serious heart disease, including: higher risk of congestive heart&#xD;
             failure, unable to control arrhythmia, unstable angina, myocardial infarction, severe&#xD;
             valvular heart disease, and resistant hypertension;&#xD;
&#xD;
          -  is not easy to control nerve, mental illness or mental disorders, compliance is poor,&#xD;
             can't cooperate with accounts and response to treatment; Primary brain tumors or CNS&#xD;
             metastases illness did not get a control, has obvious symptoms in cranial hypertension&#xD;
             or nerve spirit;&#xD;
&#xD;
          -  with bleeding tendency;&#xD;
&#xD;
          -  other researchers believe that patients should not participate in this test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han gaohua, PI</last_name>
    <role>Study Chair</role>
    <affiliation>China:Taizhou people's hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yin Qingfeng, manager</last_name>
    <phone>0086-025-85632992</phone>
    <email>y_qingfeng@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jiangsu Taizhou People's Hospital</name>
      <address>
        <city>Nanjing City</city>
        <state>Jiangsu</state>
        <zip>225499</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingfeng Yin, Clinical Manager</last_name>
      <phone>0086013912903257</phone>
      <email>y_qingfeng@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaolei Zhou, Manager</last_name>
      <phone>0086013776639377</phone>
      <email>zhouxiaolei@simcere.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <last_update_submitted>July 31, 2015</last_update_submitted>
  <last_update_submitted_qc>July 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer,Endostar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Endostar protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

